Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2109) 2109
Publication (304) 304
Book Review (28) 28
Book Chapter (18) 18
Dissertation (5) 5
Conference Proceeding (3) 3
Magazine Article (2) 2
Book / eBook (1) 1
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lapatinib (1773) 1773
humans (1292) 1292
index medicus (1262) 1262
oncology (1198) 1198
female (977) 977
trastuzumab (949) 949
breast cancer (948) 948
breast neoplasms - drug therapy (708) 708
her2 (530) 530
cancer (505) 505
breast neoplasms - pathology (449) 449
chemotherapy (443) 443
receptor, erbb-2 - metabolism (435) 435
antineoplastic agents - therapeutic use (377) 377
middle aged (363) 363
skin and connective tissue diseases (351) 351
receptor, erbb-2 - antagonists & inhibitors (349) 349
antineoplastic combined chemotherapy protocols - therapeutic use (321) 321
breast neoplasms - metabolism (312) 312
metastasis (311) 311
aged (304) 304
adult (303) 303
therapy (300) 300
open-label (298) 298
cell line, tumor (296) 296
care and treatment (289) 289
quinazolines - administration & dosage (289) 289
animals (270) 270
growth-factor receptor (262) 262
quinazolines - therapeutic use (249) 249
treatment outcome (247) 247
pharmacology & pharmacy (246) 246
tyrosine kinase inhibitor (246) 246
quinazolines - pharmacology (241) 241
survival (239) 239
epidermal growth factor (232) 232
antineoplastic agents - pharmacology (221) 221
pertuzumab (215) 215
expression (214) 214
research (214) 214
capecitabine (213) 213
receptor, erbb-2 - genetics (211) 211
antineoplastic agents (210) 210
medicine & public health (209) 209
phase-ii (208) 208
breast neoplasms - genetics (204) 204
adjuvant chemotherapy (197) 197
breast-cancer (196) 196
antimitotic agents (186) 186
resistance (184) 184
brain metastases (182) 182
lapatinib plus capecitabine (180) 180
analysis (178) 178
article (177) 177
drug therapy (177) 177
egfr (176) 176
phase-ii trial (175) 175
monoclonal-antibody (169) 169
tumors (167) 167
combination (160) 160
hematology, oncology and palliative medicine (159) 159
mice (159) 159
health aspects (149) 149
protein kinase inhibitors - pharmacology (149) 149
cancer therapies (146) 146
disease-free survival (146) 146
multicenter (146) 146
neoplasms (144) 144
drug resistance, neoplasm (143) 143
prognosis (143) 143
receptor (141) 141
growth (140) 140
male (137) 137
metastatic breast-cancer (137) 137
protein kinase inhibitors - therapeutic use (136) 136
kinases (135) 135
erbb-2 protein (134) 134
quinazolines - adverse effects (133) 133
cell biology (132) 132
metastatic breast cancer (130) 130
receptor, epidermal growth factor - antagonists & inhibitors (129) 129
clinical trials (127) 127
efficacy (126) 126
cell lung-cancer (125) 125
brain neoplasms - secondary (124) 124
tyrosine (123) 123
trial (122) 122
breast neoplasms - mortality (121) 121
activation (118) 118
antibodies, monoclonal, humanized - therapeutic use (118) 118
cell proliferation - drug effects (118) 118
neoplasm metastasis (118) 118
antineoplastic combined chemotherapy protocols - adverse effects (116) 116
signal transduction - drug effects (116) 116
erbb2 (115) 115
gefitinib (115) 115
antibodies, monoclonal, humanized (114) 114
molecular targeted therapy (114) 114
trastuzumab resistance (114) 114
neoadjuvant therapy (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2054) 2054
French (38) 38
German (16) 16
Czech (6) 6
Polish (6) 6
Chinese (4) 4
Japanese (4) 4
Spanish (4) 4
Hungarian (2) 2
Slovenian (2) 2
Turkish (2) 2
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity
by Shrivastava, Richa and Trivedi, Shruti and Singh, Pankaj Kumar and Asif, Mohammad and Chourasia, Manish Kumar and Khanna, Amit and Bhadauria, Smrati
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 09/2018, Volume 503, Issue 2, pp. 677 - 683
Breast cancer is most frequently diagnosed cancer and fifth leading cause of death in women. About 20–30% of all breast cancers overexpress HER2/neu receptors.... 
PEGylated liposomes | Lapatinib | Chorioallantoic membrane | HER2 receptor | THERAPEUTICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | TOXICITY | CHEMOTHERAPY | BREAST-CANCER | BIOPHYSICS | CLINICAL-IMPLICATIONS | INHIBITOR | Apoptosis - drug effects | Humans | Receptor, ErbB-2 - metabolism | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Cardiotoxicity - etiology | Antineoplastic Agents - administration & dosage | Lapatinib - toxicity | Antineoplastic Agents - toxicity | Breast Neoplasms - metabolism | Lapatinib - pharmacology | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Cardiotoxicity - prevention & control | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Lapatinib - therapeutic use | Breast Neoplasms - drug therapy | Chick Embryo | Protein Kinase Inhibitors - administration & dosage | Liposomes - chemistry | Animals | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Kinase Inhibitors - toxicity | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Lapatinib - administration & dosage | Antimitotic agents | Care and treatment | Epidermal growth factor | Polyethylene glycol | Analysis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out? Reply
by Harrington, KJ and Bourhis, J
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2073 - 2073
LAPATINIB | ONCOLOGY | CHEMORADIOTHERAPY | CHEMOTHERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tyrosine kinase inhibitors for human epidermal growth factor receptor 2–positive metastatic breast cancer: Is personalizing therapy within reach?
by Chien, Amy Jo and Rugo, Hope S
Journal of Clinical Oncology, ISSN 0732-183X, 09/2017, Volume 35, Issue 27, pp. 3089 - 3091
LAPATINIB | NERATINIB | TRASTUZUMAB | ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
by Rimawi, Mothaffar F and de Angelis, Carmine and Contreras, Alejandro and Pareja, Fresia and Geyer, Felipe C and Burke, Kathleen A and Herrera, Sabrina and Wang, Tao and Mayer, Ingrid A and Forero, Andres and Nanda, Rita and Goetz, Matthew P and Chang, Jenny C and Krop, Ian E and Wolff, Antonio C and Pavlick, Anne C and Fuqua, Suzanne A. W and Gutierrez, Carolina and Hilsenbeck, Susan G and Li, Marilyn M and Weigelt, Britta and Reis-Filho, Jorge S and Osborne, C. Kent and Schiff, Rachel
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2018, Volume 167, Issue 3, pp. 731 - 740
HER2-positive breast cancer | PTEN levels | Lapatinib | PIK3CA mutations | PCR | Trastuzumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Addition of amino acid moieties to lapatinib increases the anti‐cancer effect via amino acid transporters
by Maeng, Han‐Joo and Kim, Eun‐Seo and Chough, Chieyeon and Joung, Misuk and Lim, Jee Woong and Shim, Chang‐Koo and Shim, Won‐Sik
Biopharmaceutics & Drug Disposition, ISSN 0142-2782, 01/2014, Volume 35, Issue 1, pp. 60 - 69
Anti‐cancer agents delivered to cancer cells often show multi‐drug resistance (MDR) due to expulsion of the agents. One way to address this problem is to... 
lapatinib | val‐lapatinib | cancer cells | multi‐drug resistance (MDR) | tyr‐lapatinib | amino acid transporters | multi-drug resistance (MDR) | val-lapatinib | tyr-lapatinib | SYSTEM-L | DRUG | VALACYCLOVIR | GROWTH-INHIBITION | ESTER PRODRUGS | FLOXURIDINE | RECEPTOR | TUMOR-CELLS | BREAST-CANCER CELLS | GW572016 | PHARMACOLOGY & PHARMACY | Cell Survival - drug effects | Humans | Glutamine - metabolism | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - chemistry | Amino Acid Transport Systems - metabolism | Valine - chemistry | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - chemistry | Animals | Dogs | Madin Darby Canine Kidney Cells | Cell Line, Tumor | Quinazolines - administration & dosage | Quinazolines - chemistry | Tyrosine - chemistry | Amino acid transporters | Lapatinib | Val-lapatinib | Multi-drug resistance (MDR) | Tyr-lapatinib | Cancer cells | Antimitotic agents | Care and treatment | Lung cancer | Drug resistance | Antineoplastic agents | Cancer | Glutamine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
by Siravegna, Giulia and Lazzari, Luca and Crisafulli, Giovanni and Sartore-Bianchi, Andrea and Mussolin, Benedetta and Cassingena, Andrea and Martino, Cosimo and Lanman, Richard B and Nagy, Rebecca J and Fairclough, Stephen and Rospo, Giuseppe and Corti, Giorgio and Bartolini, Alice and Arcella, Pamela and Montone, Monica and Lodi, Francesca and Lorenzato, Annalisa and Vanzati, Alice and Valtorta, Emanuele and Cappello, Giovanni and Bertotti, Andrea and Lonardi, Sara and Zagonel, Vittorina and Leone, Francesco and Russo, Mariangela and Balsamo, Antonella and Truini, Mauro and Di Nicolantonio, Federica and Amatu, Alessio and Bonazzina, Erica and Ghezzi, Silvia and Regge, Daniele and Vanzulli, Angelo and Trusolino, Livio and Siena, Salvatore and Marsoni, Silvia and Bardelli, Alberto
Cancer Cell, ISSN 1535-6108, 07/2018, Volume 34, Issue 1, pp. 148 - 162.e7
Targeting HER2 is effective in 24% of amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the... 
trastuzumab | targeted therapy | rapid autopsy | colorectal cancer | clonal evolution | HER2 amplification | lapatinib | liquid biopsy | ctDNA | resistance | BREAST-CANCER | HETEROGENEITY | PIK3CA MUTATIONS | THERAPY | AMPLIFICATION | SOLID TUMORS | GENE | ONCOLOGY | ACQUIRED-RESISTANCE | EGFR BLOCKADE | PATHOLOGICAL COMPLETE RESPONSE | CELL BIOLOGY | Predictive Value of Tests | ras Proteins - genetics | Liquid Biopsy | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Protein Kinase Inhibitors - adverse effects | Time Factors | DNA Mutational Analysis | Clinical Decision-Making | Colorectal Neoplasms - drug therapy | Female | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Tumor Cells, Cultured | Liver Neoplasms - secondary | Lapatinib - adverse effects | Liver Neoplasms - genetics | Risk Factors | Liver Neoplasms - drug therapy | Trastuzumab - adverse effects | Mice, Transgenic | Treatment Outcome | Colorectal Neoplasms - diagnostic imaging | Trastuzumab - administration & dosage | Mice, SCID | Adenocarcinoma - drug therapy | Liver Neoplasms - diagnostic imaging | Adenocarcinoma - secondary | Disease Progression | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Italy | Mice, Inbred NOD | Adenocarcinoma - diagnostic imaging | Colorectal Neoplasms - pathology | Lapatinib - administration & dosage | Genetic research | Genetic aspects | Metastasis | Analysis | Colorectal cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer
by Agrawal, Satish and Dwivedi, Anil Kumar and Dwivedi, Monika and Ahmad, Hafsa and Chadchan, Sangappa Basanna and Arya, Abhishek and Sikandar, Roshan and Kaushik, Shweta and Mitra, Kalyan and Jha, Rajesh Kumar
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 02/2018, Volume 14, Issue 2, pp. 327 - 337
Lapatinib (LPT) is an orally administered drug for the treatment of metastatic breast cancer. For expanding its therapeutic horizon, we have prepared its... 
Nanocrystals | Lapatinib | Hyaluronic acid | Tykerb | Triple-negative breast cancer | THERAPEUTICS | MEDICINE, RESEARCH & EXPERIMENTAL | TUMOR | NANOSCIENCE & NANOTECHNOLOGY | KINASE INHIBITOR | PACLITAXEL | DELIVERY | LUNG METASTASIS | NANOPARTICLES | STEM-LIKE CELLS | THERAPY | DRUG NANOCRYSTALS | Nanoparticles - chemistry | Lapatinib - chemistry | Hyaluronic Acid - chemistry | Antineoplastic Agents - chemistry | Triple Negative Breast Neoplasms - drug therapy | Lapatinib - pharmacology | Xenograft Model Antitumor Assays | Animals | Triple Negative Breast Neoplasms - metabolism | Triple Negative Breast Neoplasms - pathology | Female | Hyaluronan Receptors - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Mice | Mice, Inbred BALB C | Tumor Cells, Cultured | Antimitotic agents | Breast cancer | Research institutes | Metastasis | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
by Garrett, JT and Arteaga, CL
CANCER BIOLOGY & THERAPY, ISSN 1538-4047, 05/2011, Volume 11, Issue 9, pp. 793 - 800
The antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are approved by the FDA for the treatment of HER2-overexpressing breast cancer. These... 
ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR-RECEPTOR | LAPATINIB RESISTANCE | lapatinib | MONOCLONAL-ANTIBODY | TRASTUZUMAB RESISTANCE | SOMATIC MUTATIONS | trastuzumab | tyrosine kinase inhibitors | CELL LUNG-CANCER | ONCOLOGY | HER2 (ERBB2) | METASTATIC BREAST-CANCER | DUAL PI3K/MTOR INHIBITOR | antibodies | drug resistance | DEPENDENT ACTIVATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic completeresponse in patients with early stage HER2-positive breast cancer: A meta-analysis of randomized prospective clinical trials
by Hicks, Mellissa and Macrae, Erin R and Abdel-Rasoul, Mahmoud and Layman, Rachel and Friedman, Susan and Querry, Jenny and Lustberg, Maryam and Ramaswamy, Bhuvaneswari and Mrozek, Ewa and Shapiro, Charles and Wesolowski, Robert
Oncologist, ISSN 1083-7159, 03/2015, Volume 20, Issue 4, pp. 337 - 343
Neoadjuvant chemotherapy | Breast cancer | Lapatinib | HER2 | Trastuzumab | Meta-analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells
by Janser, Félice A and Janser, Félice A and Adams, Olivia and Adams, Olivia and Bütler, Vanessa and Schläfli, Anna M and Schläfli, Anna M and Dislich, Bastian and Seiler, Christian A and Seiler, Christian A and Kröll, Dino and Kröll, Dino and Langer, Rupert and Langer, Rupert and Tschan, Mario P and Tschan, Mario P
International journal of molecular sciences, ISSN 1661-6596, 10/2018, Volume 19, Issue 10, p. 3069
Esophageal adenocarcinoma (EAC) is a highly lethal cancer type with an overall poor survival rate. Twenty to thirty percent of EAC overexpress the human... 
Her2 inhibitor | autophagy | esophageal adenocarcinoma | LC3B | OE19 | Lapatinib | p62 | resistance | Her2 | SYSTEM | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER | CHEMISTRY, MULTIDISCIPLINARY | TARGETED THERAPIES | DIFFERENTIATION | Humans | Lapatinib - therapeutic use | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Autophagy - drug effects | Lapatinib - pharmacology | Adenocarcinoma - metabolism | Esophageal Neoplasms - metabolism | HEK293 Cells | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Esophageal Neoplasms - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
by Ponde, Noam and Bradbury, Ian and Lambertini, Matteo and Ewer, Michael and Campbell, Christine and Ameels, Helene and Zardavas, Dimitrios and Di Cosimo, Serena and Baselga, José and Huober, Jens and Izquierdo, Miguel and Fumagalli, Debora and Bozovic-Spasojevic, Ivana and Maetens, Marion and Harbeck, Nadia and Pusztai, Lajos and Berghorn, Michael and Im, Young-Hyuck and Borrego, Manuel Ruiz and Chen, Dar-Ren and Rodeheffer, Richard and Piccart, Martine and Suter, Thomas and de Azambuja, Evandro
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2018, Volume 168, Issue 3, pp. 631 - 638
Biomarkers of cardiac damages, such as troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP), may be useful as early... 
Brain natriuretic peptide | Medicine & Public Health | HER2 positive breast cancer | Oncology | Lapatinib | Cardiotoxicity | Troponin T | MULTICENTER | OPEN-LABEL | MECHANISMS | EUROPEAN-SOCIETY | CHEMOTHERAPY | CLINICAL-PRACTICE GUIDELINES | HERCEPTIN ADJUVANT | 2016 ESC | ONCOLOGY | HEART-FAILURE ASSOCIATION | PLUS | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Cardiovascular Abnormalities - blood | Cardiotoxicity - pathology | Cardiovascular Abnormalities - pathology | Troponin T - blood | Drug-Related Side Effects and Adverse Reactions | Female | Paclitaxel - administration & dosage | Natriuretic Peptide, Brain - blood | Lapatinib - adverse effects | Cardiotoxicity - blood | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Biomarkers - blood | Breast Neoplasms - drug therapy | Breast Neoplasms - complications | Breast Neoplasms - pathology | Cardiovascular Abnormalities - chemically induced | Breast Neoplasms - blood | Aged | Neoplasm Staging | Lapatinib - administration & dosage | Complications and side effects | Care and treatment | Anthracyclines | Oncology, Experimental | Breast cancer | Research | Biological markers | Cancer | Natriuretic peptides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis
by Kim, JM and Miller, JA and Kotecha, R and Chao, ST and Ahluwalia, MS and Peereboom, DM and Mohammadi, AM and Barnett, GH and Murphy, ES and Vogelbaum, MA and Angelov, L and Abraham, J and Moore, H and Budd, GT and Suh, JH
NEURO-ONCOLOGY, ISSN 1522-8517, 05/2019, Volume 21, Issue 5, pp. 659 - 668
Background. Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following... 
SURVIVAL | CRITERIA | TUMOR BIOLOGY | TRASTUZUMAB | PHASE-III | lapatinib | breast cancer | CLINICAL NEUROLOGY | stereotactic radiosurgery | WOMEN | NERVOUS-SYSTEM METASTASES | ONCOLOGY | RADIATION NECROSIS | brain metastasis | HER2 | LAPATINIB PLUS CAPECITABINE | INHIBITOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile? Reply
by Dave, B and Chang, JC
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2011, Volume 29, Issue 20, pp. 3835 - 3835
LAPATINIB | TRASTUZUMAB | ONCOLOGY | RESISTANCE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Which Agents to Use Together, Which Alone, and When
by Pegram, MD
ONCOLOGY-NEW YORK, ISSN 0890-9091, 11/2015, Volume 29, Issue 11, pp. 797 - 797
LAPATINIB | TRASTUZUMAB | ONCOLOGY | PERTUZUMAB | DOCETAXEL
Journal Article
Details down arrow
15. Full Text Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays
by Wintgens, Jan P and Wichert, Sven P and Popovic, Luksa and Rossner, Moritz J and Wehr, Michael C
Cellular and Molecular Life Sciences, ISSN 1420-682X, 3/2019, Volume 76, Issue 6, pp. 1185 - 1199
Receptor tyrosine kinases (RTKs) play key roles in various aspects of cell biology, including cell-to-cell communication, proliferation and differentiation,... 
Life Sciences | Biomedicine, general | Biochemistry, general | Life Sciences, general | Cell-based assay | Lapatinib | Receptor tyrosine kinases | TEV protease | Split TEV recruitment assay | Cell Biology | BIOCHEMISTRY & MOLECULAR BIOLOGY | I RECEPTOR | FAMILY | CELL BIOLOGY | BREAST-CANCER | INSULIN | EGFR LIGANDS | EPIDERMAL-GROWTH-FACTOR | PROTEIN-PROTEIN INTERACTIONS | MULTITARGETED INHIBITORS | BINDING | ERBB RECEPTORS | A549 Cells | Reproducibility of Results | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Humans | ErbB Receptors - genetics | Rats | Biological Assay - methods | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | PC12 Cells | Pyrimidines - metabolism | src Homology Domains | Lapatinib - pharmacology | Animals | Lapatinib - metabolism | Receptor Protein-Tyrosine Kinases - genetics | GRB2 Adaptor Protein - genetics | Protein Binding - drug effects | Cell Line, Tumor | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Acrylamides - metabolism | GRB2 Adaptor Protein - metabolism | Acrylamides - pharmacology | Tyrosine | Epidermal growth factor | Proteases | Detectors | Phenols | Psychotherapy | Cells | Phosphotyrosine | Homeostasis | High-throughput screening | Homology | Antagonists | Neurodevelopmental disorders | Cell interactions | Kinases | Assaying | Recruitment | Proteins | Genetic code | Coding | Growth factors | Adaptor proteins | Cell survival | Hepatocyte growth factor | ErbB protein | Adapters | Pharmacology | Insulin | Grb2 protein | Domains | Ligands | Receptor mechanisms | Biosensors | Adapter proteins | Cancer | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes
by Marusyk, Andriy and Tabassum, Doris P and Janiszewska, Michalina and Place, Andrew E and Trinh, Anne and Rozhok, Andrii I and Pyne, Saumyadipta and Guerriero, Jennifer L and Shu, Shaokun and Ekram, Muhammad and Ishkin, Alexander and Cahill, Daniel P and Nikolsky, Yuri and Chan, Timothy A and Rimawi, Mothaffar F and Hilsenbeck, Susan and Schiff, Rachel and Osborne, Kent C and Letai, Antony and Polyak, Kornelia
Cancer Research, ISSN 0008-5472, 11/2016, Volume 76, Issue 22, pp. 6495 - 6506
Using a three-dimensional coculture model, we identified significant subtype-specific changes in gene expression, metabolic, and therapeutic sensitivity... 
LAPATINIB | HETEROGENEITY | EVOLUTION | ONCOLOGY | MEDIATED DRUG-RESISTANCE | GENE-EXPRESSION | HYALURONAN | PANCREAS CANCER | TUMOR MICROENVIRONMENT | IN-SITU | CHEMOTHERAPY | Breast Neoplasms - pathology | Humans | Cell Line, Tumor | Gene Expression Profiling - methods | Treatment Outcome | Breast Neoplasms - metabolism | Fibroblasts - metabolism | microenvironment | lapatinib resistance | breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
by Schindler, Emilie and Friberg, Lena E and Lum, Bertram L and Wang, Bei and Quartino, Angelica and Li, Chunze and Girish, Sandhya and Jin, Jin Y and Karlsson, Mats O and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för farmaceutisk biovetenskap and Uppsala universitet and Farmaceutiska fakulteten
Pharmaceutical Research, ISSN 0724-8741, 06/2018, Volume 35, Issue 6, pp. 122 - 14
Purpose An item response theory (IRT) pharmacometric framework is presented to characterize Functional Assessment of Cancer Therapy-Breast (FACT-B) data in... 
ado-trastuzumab emtansine | capecitabine | nonlinear mixed effects | lapatinib | kadcyla | T-DM1 | NONMEM | FACT-B | VALIDATION | TRANSLATION | CHEMISTRY, MULTIDISCIPLINARY | MISSING-DATA | MODELS | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | FUNCTIONAL-ASSESSMENT | TRASTUZUMAB EMTANSINE T-DM1 | ADVERSE EVENTS | Trastuzumab - therapeutic use | Maytansine - analogs & derivatives | Humans | Capecitabine - pharmacology | Lapatinib - therapeutic use | Treatment Outcome | Capecitabine - therapeutic use | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Maytansine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Lapatinib - pharmacology | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Models, Biological | Adult | Female | Trastuzumab - pharmacology | Longitudinal Studies | Patient Reported Outcome Measures | Antimitotic agents | Care and treatment | Cancer patients | Patient outcomes | Analysis | Breast cancer | Metastasis | Antineoplastic agents | Breast | Mathematical models | Exposure | Pharmacology | Patients | Trastuzumab | Metastases | Cancer | Research Paper | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
by Kang-seo Park and and Yong Sang Hong and Junyoung Choi and Shinkyo Yoon and Jihoon Kang and Deokhoon Kim and Kang-pa Lee and Hyeon-su Im and Chang Hoon Lee and Seyoung Seo and Sang-we Kim and Dae Ho Lee and Sook Ryun Park
BMB Reports, ISSN 1976-6696, 2018, Volume 51, Issue 12, pp. 660 - 665
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.... 
Lapatinib | Drug resistance | HER2 | Gastric cancer | AUY922
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text RE: Comparative Effectiveness of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis Response
by Nagayama, A and Hayashida, T and Jinno, H and Takahashi, M and Kitagawa, Y
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 04/2015, Volume 107, Issue 4
LAPATINIB | RANDOMIZED PHASE-3 TRIAL | RASH | ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis
by Kim, Joseph M and Miller, Jacob A and Kotecha, Rupesh and Chao, Samuel T and Ahluwalia, Manmeet S and Peereboom, David M and Mohammadi, Alireza M and Barnett, Gene H and Murphy, Erin S and Vogelbaum, Michael A and Angelov, Lilyana and Abraham, Jame and Moore, Halle and Budd, G. Thomas and Suh, John H
Neuro-Oncology, ISSN 1522-8517, 05/2019, Volume 21, Issue 5, pp. 659 - 668
Stereotactic radiosurgery | Brain metastasis | Breast cancer | Lapatinib | HER2
Journal Article
Details down arrow